News from ASH 2019
- PDF / 165,136 Bytes
- 2 Pages / 595 x 842 pts (A4) Page_size
- 67 Downloads / 212 Views
memo (2020) 13:247–248 https://doi.org/10.1007/s12254-020-00629-6
News from ASH 2019 Eberhard Gunsilius
Received: 9 June 2020 / Accepted: 17 June 2020 © Springer-Verlag GmbH Austria, part of Springer Nature 2020
The 61st ASH (American Society of Hematology) annual meeting and exposition was held in Orlando (FL, USA), December 7–10, 2019, with more than 25,000 attendees from more than 115 countries and almost 4900 featured abstracts. The constantly growing information overload at such “mega-meetings” does not always make it easy to keep an overview and separate the wheat from the chaff. I am happy and grateful that specialists with proven preclinical and clinical expertise in their field have agreed to do this job for us. In this issue of MEMO, selected highlights from the ASH meeting 2019 regarding chronic lymphocytic leukemia, aggressive B-cell lymphomas, multiple myeloma, and chronic myeloid leukemia are summarized by these experts. The latest developments in chimeric antigen receptor (CAR)T-cell therapy, also a main topic at ASH 2019, have been covered in the March issue of this journal [1]. Dr. Bohn and Dr. Wolf [2] summarize important clinical trials in the first-line treatment of chronic lymphocytic leukemia (B-CLL) that were presented at the meeting, illuminating the switch from nonspecific cytotoxic treatments in the past to nowadays highly specific and “chemo-free” strategies targeting malignant B-cells using tyrosine kinase inhibitors, and also address the lessons that still have to be learned. The field of aggressive B-cell lymphomas is covered by Dr. Schmitt [3]. He discusses strategies for molecular subclassification of DLBCL, explains the data from trials using modern T-cell based treatments and summarizes the good and less good news from clinical trials that implemented an immunomodulating drug (lenalidomide) or tyrosine kinase inhibitor E. Gunsilius () Medical University Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria [email protected]
K
(ibrutinib) into the standard immunochemotherapy regimen R-CHOP. Clinically meaningful and directly implementable in our daily work is the reduction of the number of R-CHOP cycles in younger patients with stage I/II DLBCL without bulky disease and other risk factors to 4 cycles if an interim PET after 3 cycles is negative without loss of long-term disease control. One of the most successful stories in the last one and a half decades that is still ongoing is the treatment of patients with multiple myeloma. Dr. Ludwig [4] highlights important clinical trials presented at the meeting as well as data on PET imaging, treatment of myeloma bone disease and clinical studies implementing novel and promising treatment approaches. Despite tremendous and actually paradigmatic achievements in the treatment of chronic myeloid leukemia (the slightly older ones remember allogeneic bone marrow transplantation as the first-line treatment for younger patients with a significant treatment-related mortality and morbidity, now replaced by taking pills in all patient
Data Loading...
